In a development that could help address the colorectal cancer screening gap, an FDA panel of experts recently recommended the approval of Shield, our innovative blood test, for primary, non-invasive screening in average-risk adults aged 45 and older. Read more about the FDA panel's recommendation and the future of colorectal cancer screening.
Guardant Health’s Post
More Relevant Posts
-
Biopharma Entrepreneur helping companies value assets, refine business cases for investor funding, and make evidence based decisions.
A question may remain as to whether an FDA advisory panel's recommended approval of a colorectal cancer blood test is a win for early screening and detection. If approved, it would not be the first blood-based screening tool available, but it is another less invasive option than colonoscopies which remain the gold standard. The upside is that an additional less invasive blood test could potentially increase diagnosis rates if it’s able to reach people who may typically refuse a colonoscopy. Fast facts: - 91% of patients with colorectal cancer detected by a colonoscopy tested positive with the blood test, so some false negatives which contribute to the controversy. - 89.9% of patients without cancer tested negative on the blood test, so some false positives - but it missed about 87% of advanced precancerous lesions, with a specificity rate of just 13.2% which is where a lot of the controversy appears to lie https://lnkd.in/eS65bGzZ #cancer #biotech #insights
A blood test to detect colon cancer is 1 step closer to FDA approval. What to know
msn.com
To view or add a comment, sign in
-
Another trial of an oral SERD on ER positive, HER2 negative, previously treated advanced breast cancer has been recently published. The results of this trial somewhat match the results of other trials, and reflect the complexity in this space. This phase II trial compared giredestrant to physician's choice. 75% of patients in the physician's choice arm received fulvestrant, while 25% received an aromatase inhibitor. In the full patient population, there was no significant difference in investigator-assessed progression-free survival (5.6 vs 5.4 months). However, a secondary endpoint analysis of only the ESR1-mutated patients showed much stronger benefit than the overall population (5.3 vs 3.5 months). This data does correlate with other trials, where the main benefit in oral SERDs comes from its activity in ESR1-mutated patients, where aromatase inhibitors/fulvestrant are less effective. Some trials, like the EMERALD trial, have shown a PFS benefit in the entire population, but in the subgroup analyses, the benefit mainly comes from the ESR1-mutated subgroup. It's possible SERDs could have a benefit in the ESR1-unmutated population because tumors cannot develop an ESR1 mutation as a mechanism of resistance. However, that should be compared against a strategy of physician's choice followed by ESR1 testing on progression, and switching to an oral SERD if the mutation has developed. At this point in the disease course, we are treating breast cancer more like a chronic disease, and should be utilizing older agents whenever possible. #breastcancer #orserdu https://lnkd.in/e2aBusUS
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
ascopubs.org
To view or add a comment, sign in
-
Optimizing Healthcare Delivery Through Collaboration & Innovation | Pulmonary & Critical Care Physician | Program Builder | MBA Candidate
🚨 New FDA Approval: First and Only Multi-targeted Chemotherapy-free Combination Regimen for Non-Small Cell Lung Cancer (NSCLC) 💊 Treatment: Lazertinib + Amivantamab combination as a first-line therapy for adult patients with locally advanced or metastatic NSCLC with certain EGFR mutations. 🔬 MARIPOSA Trial: This approval is based on the MARIPOSA Trial ↳ randomized, active-controlled, multi-center trial ↳ 1074 patients were randomized (2:2:1) to treatment with Amivanatamab + Lazertinib, Osimertinib monotherapy, or Lazertinib monotherapy. 📊 Key Stats: Improved progression-free survival (PFS) with the combination therapy. ↳ 23.7 months median PFS with the combo vs. 16.6 months with Osimertinib. ⚠️ Safety Alert: Watch out for VTE. ↳ prophylactic anticoagulation is recommended for the first 4 months of therapy. 🌟 Why It Matters: This breakthrough offers a new, chemotherapy-free option for EGFR-mutated advanced NSCLC patients. #LungCancer #FDA #Approval #PrecisionMedicine #Oncology #EGFR #Chemotherapy #Targetedtherapy #Healthcare #Innovation #BreakThrough
FDA Clears Lazertinib/Amivantamab for First-Line EGFR-Mutated NSCLC
targetedonc.com
To view or add a comment, sign in
-
📃Scientific paper: Refractory Shock Secondary to Denosumab-induced Severe Hypocalcaemia Abstract: Denosumab is one of the most commonly used antiresorptive drugs for osteoporosis treatment and the prevention of skeletal-related events in cancer patients. The purpose of this case report is to highlight potentially life-threatening severe hypocalcaemia as a side effect of denosumab complicated by refractory shock that failed to respond to medical management including intravenous calcium, vasopressors and inotropes in an elderly man with a history of prostatic cancer. LEARNING POINTS: Denosumab is a commonly used antiresorptive drugs for the treatment of osteoporosis and to prevent skeletal-related events in patients with cancer. A common side effect of denosumab is hypocalcaemia; conditions associated with a higher risk of hypocalcaemia include chronic kidney disease, pre-existing hypocalcaemia, and metastatic cancer. Severe hypocalcaemia may induce cardiovascular manifestations such as hypotension, bradycardia, impaired cardiac contractility, impaired vascular tone, and arrhythmias. Shock results from diminished vascular smooth muscle tone and tends to occur with rapid severe hypocalcaemia; it is usually refractory to fluid and pressor therapy until hypocalcaemia is corrected. Continued on ES/IODE ➡️ https://etcse.fr/9yEAz ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
Refractory Shock Secondary to Denosumab-induced Severe Hypocalcaemia
ethicseido.com
To view or add a comment, sign in
-
𝗔𝘀𝗽𝗶𝗿𝗶𝗻: 𝗛𝗲𝗮𝗱𝗮𝗰𝗵𝗲 𝗥𝗲𝗹𝗶𝗲𝗳 𝘁𝗼 𝗖𝗮𝗻𝗰𝗲𝗿 𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 Aspirin is one of the most commonly used drugs. It can help alleviate headaches and reduce fevers. Doctors also prescribe it as a cardiovascular prophylactic. Remarkably, aspirin even traveled to the moon. In the past decade, the role of aspirin has emerged as one of the most interesting and promising agents for the chemoprevention of colorectal cancer. What does this mean? A growing body of evidence has shown that people who regularly take aspirin have a lower risk of developing colorectal cancer (CRC) and are less likely to die if they do develop the disease. The mechanism behind this effect is fascinating, as it goes beyond the well-known COX inhibition. Aspirin may play a role in enhancing immunosurveillance, helping T cells identify tumor cells as foreign and destroy them. Will any company invest in large-scale clinical trials to explore this potential further? That remains unlikely...
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
thelancet.com
To view or add a comment, sign in
-
📃Scientific paper: Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan Abstract: Background Until five years ago, the metastatic hormone-sensitive prostate cancer (mHSPC) treatment landscape was dominated by the use of androgen deprivation therapy (ADT) alone. However, novel hormonal agents (NHAs) and chemotherapy are now approved for male patients with mHSPC. This study aimed to understand the impact NHA approvals had on mHSPC real-world treatment patterns and to identify the key factors associated with NHA or chemotherapy (± ADT) usage vs ADT alone. Methods Data were collected from the Adelphi Prostate Cancer Disease Specific Programme (DSP)™, a point-in-time survey of physicians and their consulting patients conducted in the United States (US), five European countries (France, Germany, Italy, Spain, and the United Kingdom), and Japan between January and August 2020. Data were analysed using descriptive statistics for individual countries, regions, and all countries combined. Pairwise analyses were used to further investigate differences between treatment groups at global level. Results 336 physicians provided data on 1195 mHSPC patients. Globally, at data collection, the most common mHSPC regimen initiated first was ADT alone (47%), followed by NHAs (± ADT) (31%, of which 21% was abiraterone, 8% was enzalutamide, and 2% was apalutamide) and chemotherapy (± ADT) (19%). The highest rates of ADT alone usage were observed in Japan (78%) and Italy (66%), and the lowest in Spain (34%) and in the US (36%). Our results showed that clinical decision ... Discover the rest of the scientific article on es/iode ➡️https://etcse.fr/Lmez
Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan
To view or add a comment, sign in
-
#immunotherapy #cancerresearch #lipids #oncology #cancertreatment https://lnkd.in/gMNxppz6 Implications for Practice In patients with advanced solid #tumours treated with immune checkpoint inhibitors, combining total #cholesterol with #triglycerides in a “lipid score” allowed us to define three subgroups of patients with different #survival benefit from immune checkpoint inhibitors. Among total cholesterol components, HDL, but not LDL, had an impact on patient survival, and combining HDL with triglycerides, we were able to define again 3 subgroups of patients with different survival benefit. The assessment of baseline patient lipid profile before immune checkpoint inhibitors therapy may represent a useful and easily available tool to guide clinical-decision making and stratify prognosis of patients’ with cancer.
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study
academic.oup.com
To view or add a comment, sign in
-
💫🌟Renal cell carcinoma🌟💫 Tom Powles The Lancet OncoAlert 🟠The management of renal cell carcinoma has evolved, improving survival in localized and advanced disease. 📈 🟠Pembrolizumab is highlighted as the first adjuvant therapy to improve overall survival in the adjuvant setting. 💊 🟠Immune checkpoint inhibitors have become the standard of care in advanced disease. 🛡️ 🟠Controversies remain in managing metastatic renal cell carcinoma, including treatment selection for frontline therapy. ⚖️ 🟠There is a need for reliable biomarkers to guide kidney cancer treatment. 🔬 👩🎓👨🎓A must-read review for all oncology fellows. Thanks to the authors. 🙌 #RenalCellCarcinoma #Oncology #CancerResearch #Pembrolizumab #Immunotherapy https://lnkd.in/daspcxgA
Renal cell carcinoma
thelancet.com
To view or add a comment, sign in
-
Oral mucositis remains a challenging side effect for many undergoing cancer therapy; however, recent studies highlight sucralfate's potential as an effective preventive agent due to its cytoprotective properties. Read the whole story here.https://https://lnkd.in/gw4siBWU
The Role Of Sucralfate In Preventing Oral Mucositis In Cancer Patients | DentalReach - Leading Dental Magazine - Dentistry Journal, News & Events
https://dentalreach.today
To view or add a comment, sign in
182,572 followers